Virios Therapeutics (VIRI) Peer Comparison
$2.74
$0.37
(15.61%)
As on 10-Dec-2024 09:30EDT
Market cap
$0 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
3.3
Div. Yield
0 %
Edit
| Virios Therapeutics (VIRI) | Longboard Pharmaceuticals (LBPH) | Lumos Pharma (LUMO) | Pieris Pharmaceuticals (PIRS) | |
|---|---|---|---|---|
Market cap ($ Mln) |
0 | 2,342 | 38 | 21 |
Revenue ($ Mln) |
-- | 0 | 2 | 1 |
Net Profit ($ Mln) |
-4.68 | -76.34 | -34.92 | -15.95 |
Net Margin (%) |
-- | -954,300.00 | -1,583.49 | -1,179.96 |
RoE (%) |
-134.80 | -25.93 | -312.41 | -83.45 |
Price to Earnings |
-- | -- | -- | -- |
Price-To-Book |
3.33 | 8.51 | 7.64 | 1.10 |
Income Statement ($ Mln)
| Virios Therapeutics (VIRI) | Longboard Pharmaceuticals (LBPH) | Lumos Pharma (LUMO) | Pieris Pharmaceuticals (PIRS) | |
|---|---|---|---|---|
|
Operating Revenue
|
0.00 | 0.00 | 2.05 | 42.81 |
|
Cost of Revenue
|
-- | 0.01 | 0.04 | 41.80 |
|
Gross Profit
|
-- | -0.01 | 2.05 | 1.01 |
|
Operating Expenses
|
5.45 | 56.76 | 38.67 | 72.57 |
|
Operating Profit (EBIT)
|
-5.45 | -56.76 | -36.61 | -29.76 |
|
Other Income
|
-- | -0.53 | -- | -- |
|
Profit before Tax
|
-5.30 | -54.42 | -34.06 | -24.54 |
|
Provision for Tax
|
-0.01 | -0.85 | -0.03 | 13.91 |
|
Profit after Tax (Net Income)
|
-5.30 | -54.42 | -34.03 | -24.54 |
|
Minority Interest
|
-- | -- | -- | -- |
|
Consolidated Profit
|
-12.25 | -43.95 | -31.06 | -- |
Liabilities ($ Mln)
| Virios Therapeutics (VIRI) | Longboard Pharmaceuticals (LBPH) | Lumos Pharma (LUMO) | Pieris Pharmaceuticals (PIRS) | |
|---|---|---|---|---|
|
Shareholder's Funds
|
3.81 | 40.92 | 27.31 | 26.76 |
|
Minority Interest
|
-- | -- | -- | -- |
|
Non-Current Liabilities
|
0.00 | 0.00 | 6.30 | 30.98 |
|
Current Liabilities
|
0.36 | 9.77 | 7.03 | 11.92 |
|
Total Liabilities
|
4.17 | 50.70 | 40.64 | 38.68 |
Assets ($ Mln)
| Virios Therapeutics (VIRI) | Longboard Pharmaceuticals (LBPH) | Lumos Pharma (LUMO) | Pieris Pharmaceuticals (PIRS) | |
|---|---|---|---|---|
|
Non-Current Assets
|
0.00 | 0.48 | 0.60 | 22.07 |
|
Current Assets
|
4.17 | 50.22 | 40.04 | 38.68 |
|
Total Assets
|
4.17 | 50.70 | 40.64 | 38.68 |
|
Total Debt*
|
-- | 0.48 | 0.59 | 13.10 |
|
Net Current Assets
|
3.81 | 40.45 | 33.01 | 36.84 |
Cashflow ($ Mln)
| Virios Therapeutics (VIRI) | Longboard Pharmaceuticals (LBPH) | Lumos Pharma (LUMO) | Pieris Pharmaceuticals (PIRS) | |
|---|---|---|---|---|
|
Cash From Operating Activities
|
-4.87 | -50.87 | -31.10 | -53.82 |
|
Cash Flow from Investing Activities
|
-- | -17.06 | -11.36 | -- |
|
Cash from Financing Activities
|
1.16 | 30.19 | -0.58 | 19.80 |
|
Net Cash Inflow / Outflow
|
-- | -55.57 | -- | -- |
Ratios
Profitability Ratios
| Virios Therapeutics (VIRI) | Longboard Pharmaceuticals (LBPH) | Lumos Pharma (LUMO) | Pieris Pharmaceuticals (PIRS) | |
|---|---|---|---|---|
|
ROCE (%)
|
-95.14 | -105.05 | -77.61 | -72.41 |
|
ROE (%)
|
-95.14 | -106.30 | -78.34 | -89.76 |
|
ROA (%)
|
-84.50 | -89.72 | -60.27 | -36.58 |
|
EBIT Margin (%)
|
-- | -- | -- | -- |
|
Net Margin (%)
|
-- | 8,161.36 | -1,659.39 | -57.33 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- |
Growth Ratios
| Virios Therapeutics (VIRI) | Longboard Pharmaceuticals (LBPH) | Lumos Pharma (LUMO) | Pieris Pharmaceuticals (PIRS) | |
|---|---|---|---|---|
|
Revenue Growth (%)
|
-- | -- | 0.35 | 0.65 |
|
EBIT Growth (%)
|
-- | -- | -- | -- |
|
Net Profit Growth (%)
|
56.52 | -26.29 | -9.57 | 21.47 |
|
EPS Growth (%)
|
-- | 0.09 | -0.12 | -- |
|
Book Value Growth (%)
|
-- | -- | -- | -- |
Valuation Ratios
| Virios Therapeutics (VIRI) | Longboard Pharmaceuticals (LBPH) | Lumos Pharma (LUMO) | Pieris Pharmaceuticals (PIRS) | |
|---|---|---|---|---|
|
Price / Earnings
|
-- | -2.65 | -0.76 | -- |
|
Price / Book Value
|
-- | 3.53 | 0.94 | -- |
|
Dividend Yield (%)
|
-- | -- | -- | -- |
|
EV/EBITDA
|
-21.98 | -1.70 | 0.27 | 1.16 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- |
Solvency Ratios
| Virios Therapeutics (VIRI) | Longboard Pharmaceuticals (LBPH) | Lumos Pharma (LUMO) | Pieris Pharmaceuticals (PIRS) | |
|---|---|---|---|---|
|
Debt to Equity
|
-- | 0.01 | 0.02 | 0.47 |
|
Short term debt to equity ratio
|
-- | 0.01 | 0.02 | 0.03 |
|
Current Ratio
|
11.62 | 5.14 | 5.69 | 3.24 |
|
Quick Ratio
|
-- | -- | -- | 2.90 |
|
Interest Coverage
|
-182.52 | -53.52 | -36.66 | -3.26 |
Operating Efficiency Ratios
| Virios Therapeutics (VIRI) | Longboard Pharmaceuticals (LBPH) | Lumos Pharma (LUMO) | Pieris Pharmaceuticals (PIRS) | |
|---|---|---|---|---|
|
Debtors to sales (%)
|
-- | -- | 10.24 | 1.34 |
|
Asset Turnover
|
0.00 | 0.00 | 0.04 | 0.64 |
|
Receivable days
|
-- | -- | 38.56 | 27.23 |
|
Inventory Days
|
-- | -- | -954.12 | 35.71 |
|
Payable days
|
-- | 84,409.28 | 4,835.41 | 32.88 |
|
Cash Conversion Cycle
|
-- | -- | -4,217.92 | 30.06 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
